Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: A potential treatment for psychotic disorders

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5310-5313

  Ito, Satoru ^a   Hirata, Yukari ^a   Nagatomi, Yasushi ^a   Satoh, Atsushi ^a   Suzuki, Gentaroh ^a   Kimura, Toshifumi ^a   Satow, Akio ^a   Maehara, Shunsuke ^a   Hikichi, Hirohiko ^a   Hata, Mikiko ^a   Ohta, Hisashi ^a   Kawamoto, Hiroshi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antagonist; Glutamate; mGluR1; Psychotic disorder

Indexed keywords

2,4 DIFLUOROBENZENE DERIVATIVE; ISOINDOLE DERIVATIVE; ISOINDOLINONE DERIVATIVE; METABOTROPIC GLUTAMATE RECEPTOR 1 ANTAGONIST; METABOTROPIC RECEPTOR 1; N ISOPROPYLISOINDOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG SYNTHESIS; IC 50; NONHUMAN; PARALLEL DESIGN; PREPULSE INHIBITION; PSYCHOSIS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; HEPATOCYTES; HUMANS; INDOLES; MICE; PSYCHOTIC DISORDERS; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 68949107534     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.145     Document Type: Article

References (18)

1. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Nat. Rev. Drug Disc. 4 (2005) 131
2. Kew J.N.C. Pharmacol. Ther. 104 (2004) 233
3. Marek G. Curr. Med. Chem.-Cent. Nerv. Syst. Agents 2 (2002) 29
4. Marino M.J., and Conn P.J. Curr. Opin. Pharmacol. 6 (2006) 98
5. Kohara A., Takahashi M., Yatsugi S.I., Tamura S., Shitaka Y., Hayashibe S., Kawabata S., and Okada M. Brain Res. 1191 (2008) 168
6. Schkeryantz J.M., Kingston A.E., and Johnson M.P. J. Med. Chem. 50 (2007) 2563
7. Suzuki G., Kimura T., Satow A., Kaneko N., Fukuda J., Hikichi H., Sakai N., Maehara S., Kawagoe-Takaki H., Hata M., Azuma T., Ito S., Kawamoto H., and Ohta H. J. Pharmacol. Exp. Ther. 321 (2007) 1144
8. Satow A., Maehara S., Ise S., Hikichi H., Fukushima M., Suzuki G., Kimura T., Tanaka T., Ito S., Kawamoto H., and Ohta H. J. Pharmacol. Exp. Ther. 326 (2008) 577
9. Ito S., Satoh A., Nagatomi Y., Hirata Y., Suzuki G., Kimura T., Satow A., Maehara S., Hikichi H., Hata M., Kawamoto H., and Ohta H. Bioorg. Med. Chem. 16 (2008) 9817
10. Sakamoto T., Uchiyama D., Kondo Y., and Yamanaka H. Heterocycles 35 (1993) 1273
11. Grey J., Dyck B., Rowbottom M.W., Tamiya J., Vickers T.D., Zhang M., Zhao L., Heise C.E., Schwarz D., Saunders J., and Goodfellow V.S. Bioorg. Med. Chem. Lett. 15 (2005) 999
12. Almansa, R. C.; Virgili, B. M. WO 2007000337, 2006; Chem. Abstr. 2006, 146, 121696.
13. John, E. A. C. In Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability; van de Waterbeemd, H., Lehhemas, H., Artursson, P., Eds.; Wiley-VCH, Weinheim, Germany; p 23.
14. Dohta Y., Yamashita T., Horiike S., Nakamura T., and Fukami T. Anal. Chem. 79 (2007) 8312
15. Lévesque J.F., Day S.H., Chauret N., Seto C., Trimble L., Bateman K.P., Silva J.M., Berthelette C., Lachance N., Boyd M., Li L., Sturino C.F., Wang Z., Zamboni R., Young R.N., and Nicoll-Griffith D.A. Bioorg. Med. Chem. Lett. 17 (2007) 3038
16. Kumar S., Kassahun K., Tschirret-Guth R.A., Mitra K., and Baillie T.A. Curr. Opin. Drug Disc. Dev. 11 (2008) 43
17. Untrecht J. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 513
18. +.